- BySeeking Alpha-
Evoke Pharma (EVOK) announces the start of additional marketing initiatives focusing on the launch of a patient and physician experience program for GIMOTI, the company’s nasal...
Evoke Pharma (EVOK) announces positive findings from a second market research study conducted for GIMOTI(metoclopramide) nasal spray.The study aimed to gather further market...
Evoke Pharma, Inc. (NASDAQ:EVOK) announced that the FDA has accepted its resubmission of 505(b)(2) new drug application (NDA) for the nasal spray product candidate, Gimoti. The...
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) announced that the first patient has been enrolled in the phase II study of its topical combination foam, FCD105, comprising minocycline...
Evoke Pharma, Inc. (Evoke) is a specialty pharmaceutical company. Evoke operates in the development and commercialization of pharmaceutical products. Evoke is focused primarily on the development and commercialization of drugs to treat gastrointestinal( GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.